



HBM IR Journal

Mar 2021

Overview

Website--Investor Access	https://www.harbourbiomed.com/investor
Market Cap (02/26 Mil)	6803.51
Total Share Capital (Mil)	767.89
Circulation Stock (Mil)	767.89

In Feb, Hongkong stock market fluctuated, various stock indexes plummeted across the board, including HSHCI and HSCI. The closing price of HSHCI fell 4.2% in last trading day compared with first trading day. Harbour stock price bears market pressure but still outperforms the market.





Announcement and Notice

- National Medical Products Administration (NMPA) granted approval of the investigational new drug (IND) application for HMB4003, a next generation, fully human anti-CTLA-4 monoclonal heavy chain only antibody in combination with PD-1 antibody with or without chemotherapy in patients with advanced non-small cell lung cancer(NSCLC) and other solid tumors. We has obtained an IND approval from US FDA and an IND approval from the NMPA In China, each for conducting a Phase I trial for HMB4003 as a monotherapy in advanced solid tumors. We has also obtained an IND approval from NMPA for HBM4003 for another combination therapy. We has commenced ongoing Phase I study in Australia.
- China Center for Drug Evaluation (CDE) has granted Breakthrough Therapy designation to batoclimab (HMB9161), our fully human anti-FcRn monoclonal antibody (mAb), for the treatment of adult patients with Myasthenia Gravis (MG). In China, an estimate of 250,000 patients suffer from this condition. Current therapies are limited due to inadequate efficacy, safety issues or limited availability.
- The company entered into agreement with AbbVie Inc. for the advancement of the development of the fully human COVID-19 neutralizing antibody 47D11, which was discovered and developed on Harbour antibody platform. Under the agreement, AbbVie will conduct the clinical development and commercialize the product worldwide.



Company News

- The company has been enrolled into Hang Seng Composite Index (HSCI) according to the quarterly review results of the Hang Seng Family of Indexes, effective on March 15, 2021. The enrollment demonstrates the strong recognition of Harbour BioMed value and potential on the capital market.
- Feb 3rd, LinGang Newly-developed District conducted the signing ceremony for newly-joined biomedical companies in this region , Harbour Biomed attended the ceremony.
- The company entered into agreement with AbbVie Inc. in Dec 2020, to advance the development of HBM9022, the fully human COVID-19 neutralizing antibody, which is discovered and developed on Harbour antibody platform. In the late stage preclinical setting, it has shown promising potential to block the infection by SARS-COV. AbbVie currently conduct the phase I clinical research worldwide.



Global Market Overview

Global Market Index

	Closing Price		
	2021.02.01	2021.02.10	2021.02.26
Dow Jones Industrial Average	30211.91	31375.83	31402.01
NASDAQ Composite Index	13403.39	14007.7	13119.43
UK FTSE 100 Index	6466.42	6531.56	6651.96
German DAX Index	13622.02	14011.8	13879.33
France CAC40 Index	5461.68	5691.54	5783.89

HK Market Index

	Closing Price		
	2021.02.01	2021.02.10	2021.02.26
HS Index	28892.86	30038.72	28980.21
HS Composite Index	4635.66	4859.58	4585.32
HS TECH	9765.89	9961.71	9496.79
HS China Enterprises Index	11454.18	11602.76	11717.41
HS Healthcare Index	7343.15	7805.72	7033.24


Global Economic Data (Feb)

Country	Items	Forecast	Actual
USA	Dallas Federal Reserve Business Activity Index	5	17.2
German	IFO Business Climate Index	90.5	92.4
France	CPI Monthly Rate	-0.30%	-0.10%
Switzerland	KOF Economic Leading Indicator	96.6	102.7
Eurozone	Industrial Prosperity Index	-5	-3.3
German	GfK Consumer Confidence Index	-14.3	-12.9
Switzerland	ZEW Investor Confidence Index	N/A	55.5

- The final value of US Markit Manufacturing PIM fell down to 58.6 from high in Feb
- GDP of Italy shrank 8.9% in 2020, annual fiscal deficit accounted for 9.5% of GDP
- German CPI increased into 1.3% in Feb, slightly higher than expected
- China Logistics Prosperity Index fell back to 49.8% in Feb
- The total value of Residential Sales and Purchasing increase 43.3% in Hong Kong in Feb

Market Overview

On 26th Feb, HSCI closed at 4585.32, down 1% from the first trading day this month. HSHCI closed at 7033.24, down 4.2% , CESHKB closed at 12534.39, down 4.56%.



HARBOUR
BIOMED



HARBOUR
BIOMED



Harbour BioMed